Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A

A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

LEARN MORE

Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A

Author(s): Blankenship Cynthia E

Issue: Sep/Oct 2014 - Volume 18, Number 5
View All Articles in Issue

Page(s): 379-380

Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A Page 1

Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A Page 2

Download in electronic PDF format for $65

Abstract:

Related Keywords: Cynthia E. Blankenship, Esq., US Food and Drug Administration, FDA, Section 503A of the Food, Drug, and Cosmetic Act, International Academy of Compounding Pharmacists, IACP, drug safety, do not compound list, bulk drug substances list, office use, repackaging, Partnership for Personalized Prescriptions

Related Categories: LEGAL, PACKAGING

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A Blankenship Cynthia E	Sep/Oct 2014 Pg. 379-380
Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA Cabaleiro Joe	Sep/Oct 2021 Pg. 358-362
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)	Nov/Dec 2016 Pg. 457-458
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Miller David G	May/Jun 2014 Pg. 208
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
The "Lists": What Do They Mean? Voliva John	Nov/Dec 2016 Pg. 477-479
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
Standing Together Fixing the Drug Quality and Security Act Miller David G	Mar/Apr 2015 Pg. 104-106

Particle Measuring Systems - USP <797> Environmental Monitoring Solutions